Collegium Pharmaceutical Inc (COLL)
Receivables turnover
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Revenue | US$ in thousands | 631,449 | 566,767 | 463,933 | 276,868 | 310,016 |
Receivables | US$ in thousands | — | — | — | — | — |
Receivables turnover | — | — | — | — | — |
December 31, 2024 calculation
Receivables turnover = Revenue ÷ Receivables
= $631,449K ÷ $—K
= —
The data indicates that Collegium Pharmaceutical Inc has a receivables turnover ratio of "—", with no specific values provided for the years from December 31, 2020, to December 31, 2024. This lack of available information makes it challenging to assess the efficiency of the company in collecting its accounts receivable within a specific period. Further data or context is necessary to evaluate the effectiveness of Collegium Pharmaceutical Inc in managing its receivables turnover efficiently.
Peer comparison
Dec 31, 2024
Company name
Symbol
Receivables turnover
Collegium Pharmaceutical Inc
COLL
—
Abbott Laboratories
ABT
—
AbbVie Inc
ABBV
—
ACADIA Pharmaceuticals Inc
ACAD
—
Alkermes Plc
ALKS
4.05
Amphastar P
AMPH
5.37
ANI Pharmaceuticals Inc
ANIP
—
Arcus Biosciences Inc
RCUS
51.60
Biomarin Pharmaceutical Inc
BMRN
4.31
Bristol-Myers Squibb Company
BMY
4.49
Catalyst Pharmaceuticals Inc
CPRX
—